NRAS and acute myeloid leukemia: This novel mechanism of EF-24 discovered in our study not only provides further insights into its antileukemic potential, but also contributes to developing EF-24 as a useful PP2A-activating agent for treating AML, especially in patients with the NRAS or FLT3 mutation.